1 2 3 4 5

читать далее ... Heart J., 2002, 15, 1190-1201. 2. Cambou J., Danchin N., Boutaibi Y. et al. [Evolution of the management and outcomes of patients admitted for acute myocardial infarction in France from 1995 to 2000: data from the USIK. 1995 and USIC 2000 nationwide registries]. Ann. Cardiol. Angeiol. (Paris), 2004, 53 (1), 12-17. 3. Steffenino G., Santoro G., Maras P. et al. In-hospital and one-year outcomes of patients with high-risk acute myocardial infarction treated with thrombolysis or primary coronary angioplasty. Ital. Heart J., 2004, 5 (2), 136-145. 4. Pfeffer M., Braunwald E., Moye L. et al. Effect ofcaptopnl on mortality and morbidity in patients with left ventncular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 1992, 327 (10), 669-677. 5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342. 821-828. 6. Кн>Ьег L., Torp-Pedersen С., Carlsen J. et al. A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventncular dysfunction after myocardial infarction. N. Engl. J. Med., 1995, 333. 1670-1676. 7. Dickstein К., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPT1MAAL randomised trial. Lancet, 2002, 360, 752-760. 8. Dickstein К. What did we learn from the OPT1MAAL trial? What can we expect from VALIANT? Am. Heart J., 2003, 145, 754-757. 9. Pfeffer M., McMurray J., Velazquez E. et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular Dysfunction, or both. N. Engl. J. Med , 2003, 349, 1893-1906. 10. Anavekar A., McMurray J., Velazquez E et al. Influence of renal function on one-year cardiovascular outcomes in the VALIANT trial. Circulation, 2003, 106 (17, suppl.), IV-485.Источник: Клиническая фармакология и терапия. 2005. №3. С.14-18